Status:
UNKNOWN
Ketamine for Mood Disorders With Suicidal Ideation
Lead Sponsor:
The Miriam Hospital
Conditions:
Depressive Disorder, Major
Suicidal Ideation
Eligibility:
All Genders
18-65 years
Phase:
EARLY_PHASE1
Brief Summary
This study will explore whether the use of a medication, Ketamine, can help patients who come to the ER with thoughts of suicide by improving their mood and reducing thoughts of suicide. Ketamine has ...
Detailed Description
Mood disorders complicated by suicidal ideation (SI) are common among patients presenting to the Emergency Department (ED). Under current standard practice, patients awaiting psychiatric evaluation in...
Eligibility Criteria
Inclusion
- English speaking
- between 18 and 65 years of age
- have active suicidal ideation as determined by psychiatry staff
- are being admitted to psychiatry under voluntary certification and are able to provide informed consent.
Exclusion
- have been previously enrolled in the trial
- are pregnant or breastfeeding; have a known or suspected allergy to ketamine; have used ketamine within 24h of presentation
- require antipsychotics (prescription or PRN by ED staff) or ED administration of other mood-altering medications for the management of acute agitation
- have known renal or liver failure; have neurologic, respiratory, or hemodynamic compromise as determined by the treating ED physician
- have history of stroke or cardiac disease (prior MI, cardiac stents or bypass surgery); or are incarcerated
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04099771
Start Date
July 1 2019
End Date
December 31 2021
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Miriam Hospital
Providence, Rhode Island, United States, 02905